Kiniksa Pharmaceuticals International, plc KNSA
Nov 10, 2026, 9:33 AM EST
- YTD
- +136.55%
- 1 year
- +154.30%
- Market cap
- 7.67B
- Revenue (ttm)
- 945.96M
- Profit margin
- 11.58%
- EPS (ttm)
- 1.32
- Shares out
- 48.84M
- P/E ratio
- 73.92
- Forward P/E
- 45.25
- YTD return
- +136.55%
- 1-year return
- +154.30%
- Volume
- 12.46K
- Avg volume
- 663.39K
- Open
- 97.35
- Previous close
- 98.76
- Day's range
- 96.39 – 98.37
- 52-week range
- 37.02 – 99.31
- Beta
- 0.08
- Analysts
- Strong Buy
- Price target
- 109.43 (+12.1%)
- Earnings date
- Feb 23, 2027
5D +6.70 (+7.28%)
Key statistics
- Enterprise value
- 6.81B
- PEG ratio
- 0.00
- Price / sales
- 8.20
- Price / book
- 10.91
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 58.10%
- Free cash flow
- 135.87M
- Total cash
- 568.76M
- Total debt
- 7.88M
- Return on equity
- 17.59%
- Short % of float
- 9.31%
- 50-day average
- 80.46
- 200-day average
- 61.50
Analyst view
Consensus: strong buy
- Target (low)
- 98.00
- Target (mean)
- 109.43
- Target (high)
- 134.00
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.275.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.2511 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | 0.371 | 0.56 | +0.19 | +50.94% |
| Jul 28, 2026 | Jun 30, 2026 | 0.2995 | 0.30 | 0.00 | +0.17% |
| Apr 28, 2026 | Mar 31, 2026 | 0.18 | 0.27 | +0.09 | +50.00% |
| Feb 24, 2026 | Dec 31, 2025 | 0.29 | 0.17 | -0.12 | -41.38% |
| Oct 28, 2025 | Sep 30, 2025 | 0.33 | 0.23 | -0.10 | -30.30% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 28, 2026 | Goldman Sachs | main | Buy | Buy |
| Oct 28, 2026 | Wedbush | main | Outperform | Outperform |
| Oct 28, 2026 | Wells Fargo | main | Overweight | Overweight |
| Jul 30, 2026 | Goldman Sachs | main | Buy | Buy |
| Jul 29, 2026 | JP Morgan | main | Overweight | Overweight |
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United Kingdom
- Website
- kiniksa.com
News
AlphaCentric Advisors LLC Acquires New Position in Kiniksa Pharmaceuticals International, plc $KNSA 
Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum Stock 
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122 
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101 
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102 - Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Crude Oil Moves Lower; Corning Earnings Top Views 
Pentair, JetBlue Airways, Hawkins And Other Big Stocks Moving Higher On Tuesday 
Kiniksa Pharmaceuticals Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on KNSA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Unknown | Stock Award(Grant) | May 28, 2026 | 0 |
| BAKER BROTHERS LIFE SCIENCES, L.P. | Director | Stock Award(Grant) | Jun 2, 2025 | 0 |
| LEVY RICHARD S | Director | Conversion of Exercise of derivative security | Jul 30, 2026 | 22,359 |
| MALLEY THOMAS ROBERT | Director | Conversion of Exercise of derivative security | May 28, 2026 | 87,312 |
| MCCAIN TRACEY LORENE | Director | Conversion of Exercise of derivative security | May 28, 2026 | 15,345 |
| PAOLINI JOHN F | Officer | Conversion of Exercise of derivative security | Nov 1, 2026 | 69,922 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 17.30% | 6,971,361 | 688.49M | Jun 29, 2026 |
| Rubric Capital Management LP | 9.92% | 3,999,800 | 395.02M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 7.03% | 2,834,643 | 279.95M | Jun 29, 2026 |
| Blackrock Inc. | 6.80% | 2,739,615 | 270.56M | Jun 29, 2026 |
| Tang Capital Management, LLC | 5.61% | 2,259,889 | 223.19M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.74% | 1,911,335 | 188.76M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.27% | 1,318,452 | 130.21M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.93% | 1,180,466 | 116.58M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 2.58% | 1,040,000 | 102.71M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.37% | 954,719 | 94.29M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.89% | 761,824 | 75.24M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.58% | 637,600 | 62.97M | Sep 29, 2026 |